Biggest News Aggregation in the World
📰 Thomas Shrader News

Page 2 - Thomas Shrader News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Thomas Shrader. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

G1 Therapeutics, inc (GTHX) Q2 2021 Earnings Call Transcript

Operator Good day. Thank you for standing by, and welcome to the G1 Therapeutics Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] I would now like to turn the conference over to your host, Mr. Will Roberts. Please go ahead, sir. William Roberts -- Vice President of Investor Relations & Corporate Communications T...
United States Andrew Perry Tony Butler Jack Bailey David Nierengarten Joseph Thome Cowen
Source: fool.com

Esperion Therapeutics, inc (ESPR) Q2 2021 Earnings Call Transcript

Operator Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions]. Following the presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir. Benjamin Church -- Head, Corporate Communications & Investor Relations Thank you, operator. Good morning and welcome to Esperions Second Quarter 2021 Financial Re...
United States United Kingdom Morgan Stanley Rick Bartram Sheldon Koenig Jessica Fye
Source: fool.com

Biogen (BIIB) Receives a Hold from BTIG

Markets BTIG analyst Thomas Shrader maintained a Hold rating on Biogen (BIIB – Research Report) on April 22. The company’s shares closed last Friday at $262.63. According to TipRanks.com, Shrader is a 4-star analyst with an average return of 18.6% and a 41.2% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics, Stoke Therapeutics, and Gain Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bi...
Thomas Shrader Research Report On Biogen Inc Research Report Voyager Therapeutics Stoke Therapeutics
Source: markets.co

Stroke | Benzinga

Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firms Thomas Shrader upgrades Biogens stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in... Read More... Dont Miss Any Updates! News Directly in Your Inbox Subscribe to:
Thomas Shrader Biogen Inc தாமஸ் ஷ்ராதேற் பயோஜென் இன்க்

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science